To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
MannKind Corporation
MannKind Corporation (Nasdaq:MNKD ) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America to study its safety and efficacy in the treatment of diabetes. Additional recommended knowledgeMannKind is focusing on three areas. First, we are continuing to execute the Technosphere® Insulin clinical trial program. Second, we are moving our second potential product – a therapeutic cancer vaccine – through Phase 1 clinical trials. Third, we have begun clinical testing of the next product candidate for use with our Technosphere® platform technology. http://www.mannkindcorp.com |
||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "MannKind_Corporation". A list of authors is available in Wikipedia. |